347 related articles for article (PubMed ID: 12091329)
1. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.
Lee SJ; Klein JP; Barrett AJ; Ringden O; Antin JH; Cahn JY; Carabasi MH; Gale RP; Giralt S; Hale GA; Ilhan O; McCarthy PL; Socie G; Verdonck LF; Weisdorf DJ; Horowitz MM
Blood; 2002 Jul; 100(2):406-14. PubMed ID: 12091329
[TBL] [Abstract][Full Text] [Related]
2. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
3. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
[TBL] [Abstract][Full Text] [Related]
4. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome.
Zecca M; Prete A; Rondelli R; Lanino E; Balduzzi A; Messina C; Fagioli F; Porta F; Favre C; Pession A; Locatelli F;
Blood; 2002 Aug; 100(4):1192-200. PubMed ID: 12149197
[TBL] [Abstract][Full Text] [Related]
5. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
MacMillan ML; Weisdorf DJ; Wagner JE; DeFor TE; Burns LJ; Ramsay NK; Davies SM; Blazar BR
Biol Blood Marrow Transplant; 2002; 8(7):387-94. PubMed ID: 12171485
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
7. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
9. Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia.
Boyiadzis M; Arora M; Klein JP; Hassebroek A; Hemmer M; Urbano-Ispizua A; Antin JH; Bolwell BJ; Cahn JY; Cairo MS; Cutler CS; Flowers ME; Gale RP; Herzig R; Isola LM; Jacobsohn DA; Jagasia MH; Klumpp TR; Lee SJ; Petersdorf EW; Santarone S; Spellman SR; Schouten HC; Verdonck LF; Wingard JR; Weisdorf DJ; Horowitz MM; Pavletic SZ
Clin Cancer Res; 2015 May; 21(9):2020-8. PubMed ID: 25348512
[TBL] [Abstract][Full Text] [Related]
10. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Bhatt VR; Wang T; Chen K; Kitko CL; MacMillan ML; Pidala JA; Al Malki MM; Badawy SM; Beitinjaneh A; Ganguly S; Hamilton B; Hildebrandt GC; Lekakis LJ; Liu H; Maziarz RT; Modi D; Murthy HS; Preussler JM; Sharma A; Spellman SR; Arora M; Lee SJ
Transplant Cell Ther; 2022 Jan; 28(1):34-42. PubMed ID: 34637965
[TBL] [Abstract][Full Text] [Related]
11. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
12. Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.
Enright H; Davies SM; DeFor T; Shu X; Weisdorf D; Miller W; Ramsay NK; Arthur D; Verfaillie C; Miller J; Kersey J; McGlave P
Blood; 1996 Jul; 88(2):714-20. PubMed ID: 8695820
[TBL] [Abstract][Full Text] [Related]
13. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
14. [Impact of chronic graft-versus-host disease on long-term outcome after allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia].
Wojnar J; Giebel S; Hołowiecka-Goral A; Krawczyk-Kuliś M; Markiewicz M; Stella-Hołowiecka B; Wylezoł I
Pol Arch Med Wewn; 2006 Jul; 116(1):671-7. PubMed ID: 17340974
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
[TBL] [Abstract][Full Text] [Related]
16. Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.
Kumar AJ; Kim S; Hemmer MT; Arora M; Spellman SR; Pidala JA; Couriel DR; Alousi AM; Aljurf MD; Cahn JY; Cairo MS; Cutler CS; Farhan S; Gergis U; Hale GA; Hashmi SK; Inamoto Y; Kamble RT; Kharfan-Dabaja MA; MacMillan ML; Marks DI; Nakasone H; Norkin M; Qayed M; Ringden O; Schouten HC; Schultz KR; Solh MM; Teshima T; Urbano-Ispizua A; Verdonck LF; Gale RP; Hamilton BK; Majhail NS; Loren AW
Blood Adv; 2018 May; 2(9):1022-1031. PubMed ID: 29739773
[TBL] [Abstract][Full Text] [Related]
17. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial.
Flowers ME; Parker PM; Johnston LJ; Matos AV; Storer B; Bensinger WI; Storb R; Appelbaum FR; Forman SJ; Blume KG; Martin PJ
Blood; 2002 Jul; 100(2):415-9. PubMed ID: 12091330
[TBL] [Abstract][Full Text] [Related]
18. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
[TBL] [Abstract][Full Text] [Related]
20. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.
van Rood JJ; Loberiza FR; Zhang MJ; Oudshoorn M; Claas F; Cairo MS; Champlin RE; Gale RP; Ringdén O; Hows JM; Horowitz MH
Blood; 2002 Mar; 99(5):1572-7. PubMed ID: 11861270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
